Clinical study of Anlotinib as Third-Line or Further Treatment on Advanced Epithelial Ovarian Cancer

Oncology Department, Guangdong Provincial Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Aged 18-75 years;
•(2) Epithelial ovarian cancer was diagnosed by pathology or cytology.
•(3) The stage of diagnosis is stage IV or after the previous radical treatment, recurrence and metastasis are re-staged to stage IV;
•(4) After the first-line and second-line treatmentthe tumor progresses again;
•(5) Behavioral status PS (ECOG) 0-2;
•(6) The estimated survival time is greater than 3 months;
•(7) Normal function of bone marrow, liver and kidney:
•Hb (hemoglobin) >= 80g / L;
•NEUT (neutrophil count) >= 1.5*10^9 / L;
•PLT (platelet) >= 90*10^9 / L;
•Alanine aminotransferase (ALT)<= 2.5*upper limit of normal(ULN) (if combined with liver metastasis, ALT <= 5* ULN);
•Total bilirubin (TB) <= 1.5 * ULN;
•Protein (ALB) >= 30g / L;
•Creatinine (Scr) <= 1.5 * ULN;
•(8) Knowing to participate in the study, sign the informed consent, good compliance and can follow-up;
•(9) Women in childbearing age were negative for pregnancy test (blood/urine hCG) within 7 days. And ensured effective contraception during the trial and within 6 months after the end of the trial.

•(1) Combined with hypertension and poor drug control, the blood pressure after standard antihypertensive treatment is higher than 140/90mmHg;
•(2) Combined bleeding risk;
•(3) Concomitant merger of other malignant tumors within five years;
•(4) Those who combine active tuberculosis and other serious infectious diseases;
•(5) Patients who have received radiotherapy;
•(6) Has received other anti-angiogenic drugs;
•(7) There are serious brain diseases or mental illnesses that affect the patient's ability to complain privately;
•(8) With the history of organ transplantation;
•(9) Participated in other clinical studies within 4 weeks;
•(10) Pregnant or lactating women.

发起方

Oncology Department, Guangdong Provincial Hospital of Chinese Medicine